Symvivo
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8900 Glenlyon Pkwy, Burnaby, British Col...Phone Number
(604) 428-7474Website
www.symvivo.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Symvivo
Symvivo, founded in 2013 and headquartered in Burnaby, Canada, is a clinical-stage gene therapy company developing oral DNA vaccines for life-threatening diseases, such as COVID-19, with broader therapeutic potential for IV therapeutics in cancer and genetic diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Symvivo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Symvivo has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Symvivo launches new products
Congratulate Masked Content for being promoted to Masked Content at Symvivo
Symvivo, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Symvivo had a recent Job posting/layoffs
Earning: See what the market has to say on Symvivo recently announced quarterly report
Funding: Get notified immidiatlly once Symvivo has new funding data
Check out if Symvivo is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Symvivo
Compare insights from companies similar to Symvivo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Symvivo
<$5M
11-50
Private
<$5M
2013
N/A
Company Profile Activity
Activity Insights
Symvivo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Symvivo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Symvivo.
Symvivo financials insights
Gather financial insights about Symvivo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Grant
$2.8M
2022
Grant
$650K
Symvivo Tech Stack
A closer look at the technologies used by Symvivo
Symvivo News & Media
Symvivo Corporation Announces Collaboration with Merck
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines. “We are excited to be collaborating with Merck on this novel prSymvivo Corporation Announces Research Collaboration With Janssen
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the exclusive option to research, develop and commercialize novel biological therapeutic candidates based on Symvivo’s baFirst Healthy Volunteer Dosed in Symvivo’s Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, today announced the enrollment and dosing of the first healthy volunteer in a clinical trial in Australia evaluating its bacTRL-Spike™ oral vaccine candidate for the prevention of COVID-19. “We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for futureSymvivo Corporation Receives Funding for COVID-19 Vaccine Program
BURNABY, British Columbia--(BUSINESS WIRE)--Symvivo Corporation today announced that it is receiving advisory services and funding of up to $2.8 million from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike™, the company’s oral, room temperature-stable DNA vaccine candidate for the prevention of COVID-19. The funding follows a notification Symvivo received from the Government of Canada indicating it had reviewed
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Symvivo
Sign Up For FreeTo access detailed company insights
Symvivo, founded in 2013 and headquartered in Burnaby, Canada, is a clinical-stage gene therapy company developing oral DNA vaccines for life-threatening diseases, such as COVID-19, with broader therapeutic potential for IV therapeutics in cancer and genetic diseases.... Read More
